Physician profile
Robert Shmuts
NPI 1427203694
$3,291.33
in general payments reported to CMS, 2019-2025
26 companies · $631 in 2025
The $631 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $694 · 2020: $334 · 2021: $384 · 2022: $347 · 2023: $276 · 2024: $626 · 2025: $631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,518 · Education: $14.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,518.05 |
| Education | $14.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,297.59 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $250.28 | 2019-2024 | Entyvio |
| Celgene Corporation | $236.47 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $178.83 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Abbvie INC. | $166.69 | 2019-2025 | Viberzi, Linzess |
| Pfizer INC. | $150.74 | 2019-2023 | |
| Lilly USA, LLC | $140.07 | 2024-2025 | Omvoh |
| Braintree Laboratories, INC. | $92.88 | 2019-2022 | |
| Redhill Biopharma INC. | $91.20 | 2020-2023 | |
| Regeneron Healthcare Solutions, INC. | $87.64 | 2023-2025 | Dupixent |
| Ferring Pharmaceuticals INC. | $86.38 | 2019-2023 | Rebyota |
| Genzyme Corporation | $78.79 | 2024-2025 | |
| Madrigal Pharmaceuticals | $75.38 | 2024-2025 | Rezdiffra, Resmetirom |
| Daiichi Sankyo INC. | $48.80 | 2019 | |
| Qol Medical, LLC | $42.37 | 2024 | Sucraid |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $41.81 | 2019-2020 | |
| Boston Scientific Corporation | $40.21 | 2024 | Watchman |
| Allergan, INC. | $34.60 | 2019 | |
| Evoke Pharma, INC. | $30.23 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $23.11 | 2019-2020 | |
| Ardelyx, INC. | $19.19 | 2024 | Ibsrela |
| Celltrion USA INC. | $18.02 | 2025 | Vegzelma |
| Ge Healthcare | $16.81 | 2025 | |
| Capsovision, INC. | $15.17 | 2023 | Capsocam Plus |
| Phathom Pharmaceuticals, INC. | $14.79 | 2025 | Voquezna |
| Shire North American Group INC | $13.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Shmuts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.